✦ LIBER ✦

Pegylated interferon plus ribavirin in chronic hepatitis c

✍ Scribed by Bruce R. Bacon

Book ID: 107537830
Publisher: Springer
Year: 2001
Tongue: English
Weight: 38 KB
Volume: 3
Category: Article
ISSN: 1522-8037
DOI: 10.1007/s11894-001-0046-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated interferon alpha-2b plus ribav

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues

✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Interleukin 28B polymorphism predicts pe

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4

✍ Stella De Nicola; Alessio Aghemo; Maria Grazia Rumi; Enrico Galmozzi; Luca Valen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 1 views

Single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) region are the strongest baseline predictors of a sustained virologic response (SVR) to peg-interferon (PegIFN) and ribavirin (Rbv) in patients with hepatitis C virus (HCV) genotype 1 infection. Whether this holds true for HCV-4

Pegylated interferon α-2b plus ribavirin

Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients

✍ Esther Voigt; Christian Schulz; Gerd Klausen; Joerg Goelz; Stefan Mauss; Guenthe 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Efficacy of re-treatment with pegylated

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

✍ Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide O 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 297 KB

Randomized trial comparing pegylated int

Randomized trial comparing pegylated interferon α-2b versus pegylated interferon α-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

✍ Montserrat Laguno; Carmen Cifuentes; Javier Murillas; Sergio Veloso; Maria Larro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB

Neutralizing antibodies to interferon-α

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

✍ Philippe Halfon; Sophie Pérusat; Marc Bourlière; Jean-Pierre Bronowicki; Pascale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract A lack of antiviral response in patients with chronic hepatitis C treated with pegylated (PEG)‐interferon (IFN)‐α‐2a + ribavirin (RIBA) may be explained by neutralizing antibodies to IFN‐α‐2a. The aim of this study was to assess neutralizing antibodies to IFN‐α‐2a and IFN levels in non‐